loading...| Preferred Name |
gefitinib |
|
| Synonyms |
ZD 1839 4-(3chloro-4-flurophenylamine)-7-methoxy-6(3-(4morpholinyl)quinazoline N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) propoxy]-4-quinazolinamine ZD1839 Iressa 4-quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-4-morpholin] propoxy] |
|
| Definitions |
An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1855" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1855" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000043649 |
|
| altLabel |
ZD 1839 4-(3chloro-4-flurophenylamine)-7-methoxy-6(3-(4morpholinyl)quinazoline N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) propoxy]-4-quinazolinamine ZD1839 Iressa 4-quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-4-morpholin] propoxy] |
|
| CAS Registry |
184475-35-2 |
|
| Component of |
http://purl.bioontology.org/ontology/PDQ/CDR0000038502 http://purl.bioontology.org/ontology/PDQ/CDR0000038473 http://purl.bioontology.org/ontology/PDQ/CDR0000038591 http://purl.bioontology.org/ontology/PDQ/CDR0000258295 http://purl.bioontology.org/ontology/PDQ/CDR0000330111 http://purl.bioontology.org/ontology/PDQ/CDR0000365678 http://purl.bioontology.org/ontology/PDQ/CDR0000038432 http://purl.bioontology.org/ontology/PDQ/CDR0000438775 http://purl.bioontology.org/ontology/PDQ/CDR0000038666 http://purl.bioontology.org/ontology/PDQ/CDR0000377335 http://purl.bioontology.org/ontology/PDQ/CDR0000037949 http://purl.bioontology.org/ontology/PDQ/CDR0000370023 http://purl.bioontology.org/ontology/PDQ/CDR0000406030 http://purl.bioontology.org/ontology/PDQ/CDR0000298864 http://purl.bioontology.org/ontology/PDQ/CDR0000370022 http://purl.bioontology.org/ontology/PDQ/CDR0000038445 http://purl.bioontology.org/ontology/PDQ/CDR0000350217 http://purl.bioontology.org/ontology/PDQ/CDR0000037998 http://purl.bioontology.org/ontology/PDQ/CDR0000373823 http://purl.bioontology.org/ontology/PDQ/CDR0000433202 http://purl.bioontology.org/ontology/PDQ/CDR0000306450 |
|
| cui |
C0919281 C1122962 C0879396 |
|
| Date last modified |
2016-04-26 |
|
| definition |
An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1855" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1855" NCI Thesaurus) |
|
| IND Code |
61187 |
|
| Legacy PDQ ID |
8948 |
|
| LT |
TRD |
|
| NCI ID |
C1855 |
|
| notation |
CDR0000043649 |
|
| NSC Code |
715055 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
gefitinib |
|
| tui |
T109 T121 |